The FDA is trending regarding duloxetine due to recalls of the popular antidepressant. These recalls are prompted by the detection of elevated levels of nitrosamine impurities, a compound with potential carcinogenic risks.
Get the full breakdown — why it matters, background context, and what comes next.
Read Full Analysis